Otsuka’s Voyxact (anti-APRIL) advanced IgA nephropathy expectations with Phase III eGFR-slope results suggesting the drug may halt or reverse kidney function decline. The data were highlighted as raising the bar for the anti-APRIL class and for differentiation versus existing approaches. For nephrology stakeholders, the focus is on whether eGFR slope can translate into durable clinical outcomes and long-term safety as the program moves closer to regulatory milestones. The results also shape competitive strategy among biologics targeting APRIL/BAFF-related pathways in immune-mediated kidney disease.